Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × Nivolumab × 1 year × Clear all

Status

Active not recruiting 231 Recruiting 170 Completed 149 Terminated 40 Not yet recruiting 23 Withdrawn 6 Suspended 6 Enrolling by invitation 2 No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Interventions

Suspensions 2 Powders 2 zanidatamab 1 trametinib 1 taletrectinib 1 ruxolitinib 1 revumenib 1 patritumab deruxtecan 1 omburtamab I-131 1 omaveloxolone 1 leronlimab 1 derazantinib 1 dabrafenib 1 capmatinib 1 asparaginase erwinia chrysanthemi recombinant 1 apalutamide 1 Standard of Care 1 Paclitaxel 1 Nivolumab 1 HMPL-013 1 Everolimus 1 Docetaxel 1 Asparaginase 1 Androgen Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06590480 2025-12-18

RPL-EAP-001

Replimune Inc.

No longer available

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡